Business

Disruptive Innovation, Uncertain Value, and Economic Modeling in Oncology

by Michael F. Murphy, MD, PhD

Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend

Christopher M. Blanchette, PhD, MBA, Nicholas J. Gross, MD, PhD, Pablo Altman, MD, MBA, F. Randy Vogenberg, PhD

April 2014 Vol 7, No 2 - Business

Stakeholder Perspective

Chronic Obstructive Pulmonary Disease Remains a Growing Population Health Concern

Resource Utilization and Cost in a Commercially Insured Population with Schizophrenia

Kathryn Fitch, RN, MEd, Kosuke Iwasaki, FIAJ, MAAA, Kathleen F. Villa, MS

January/February 2014 Vol 7, No 1 - Business

Stakeholder Perspective

Schizophrenia: “The Forgotten Illness”?

by Atheer Kaddis, PharmD

Insurance Companies’ Perspectives on the Orphan Drug Pipeline

Robert Handfield, PhD, Josh Feldstein, BA

November/December 2013, Vol 6, No 9 - Business

Stakeholder Perspective

Breakthrough Therapy, or Breakthrough Pricing?

by Atheer Kaddis, PharmD

Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR

Andrew Paris, MBA, Chris M. Kozma, PhD, Wing Chow, PharmD, MPH, Anisha M. Patel, MS, Samir H. Mody, PharmD, MBA, Myoung S. Kim, PhD, MBA

November/December 2013, Vol 6, No 9 - Business

Stakeholder Perspective

Can Substituting Generic Drugs with Brand-Name Agents for Acute Pain Postsurgery Help to Deliver Cost-Effective, Quality Care?

by Matthew Mitchell, PharmD, MBA, FAMCP

The Economics of Biosimilars

Erwin A. Blackstone, PhD, Joseph P. Fuhr, Jr, PhD

September/October 2013, Vol 6, No 8 - Business

Stakeholder Perspective

Modeling the Future Economic Impact of Biosimilars’ Entry into the US Market

by Grant D. Lawless, RPh, MD, FACP

The Incidence Rate and Economic Burden of Community-Acquired Pneumonia in a Working-Age Population

Jonah Broulette, ASA, MAAA, Holly Yu, MSPH, Kosuke Iwasaki, FIAJ, MAAA, Reiko Sato, PhD, Bruce S. Pyenson, FSA, MAAA

September/October 2013, Vol 6, No 8 - Business

Stakeholder Perspective

CAP Is a Burden for All Ages—Prevention Strategies Are Key

by F. Randy Vogenberg, PhD

Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: Current and Future Pharmacologic Approaches to Improving Outcomes

Mary Ann Banerji, MD, FACP, Jeffrey D. Dunn, PharmD, MBA, Jeffrey A. Bourret, PharmD

September 2013, Vol 6, No 7 - Business

Stakeholder Perspective

Innovation in Patient Engagement and Management Is Critically Needed to Change Current Trends in Type 2 Diabetes

Communication Strategies Must Be Tailored to a Medication’s Targeted Population: Lessons from the Case of BiDil

Chamika Hawkins-Taylor, MHA, PhD, Angeline M. Carlson, PhD

September 2013, Vol 6, No 7 - Business

Stakeholder Perspective

Much More than Biomarkers: Sociodemographic Variables in Personalized Medicine

by Michael F. Murphy, MD, PhD

Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases

Marie-Hélène Lafeuille, MA, Jonathan Gravel, MSc, Amanda Grittner, MA, Patrick Lefebvre, MA, Lorie A. Ellis, PhD, Scott McKenzie, MD

July/August 2013 Vol 6, No 6 - Business

Stakeholder Perspective

“Roid Rage”

by Atheer Kaddis, PharmD

Start «2 3 4 5 678 9 10 11 »End

Page 7 of 13
Results 61 - 70 of 128